Aspiriant LLC Sells 7,821 Shares of Tempus AI, Inc. $TEM

Aspiriant LLC cut its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 57.1% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 5,872 shares of the company’s stock after selling 7,821 shares during the quarter. Aspiriant LLC’s holdings in Tempus AI were worth $373,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. First Horizon Advisors Inc. grew its position in Tempus AI by 12.7% during the 1st quarter. First Horizon Advisors Inc. now owns 1,849 shares of the company’s stock worth $89,000 after acquiring an additional 208 shares during the last quarter. Concord Wealth Partners grew its holdings in shares of Tempus AI by 308.0% during the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Tempus AI by 59.9% in the second quarter. Farther Finance Advisors LLC now owns 884 shares of the company’s stock valued at $56,000 after buying an additional 331 shares during the period. Bartlett & CO. Wealth Management LLC increased its stake in shares of Tempus AI by 100.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company’s stock valued at $39,000 after buying an additional 400 shares during the period. Finally, Axxcess Wealth Management LLC raised its holdings in Tempus AI by 6.2% in the 2nd quarter. Axxcess Wealth Management LLC now owns 8,190 shares of the company’s stock valued at $520,000 after buying an additional 481 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TEM shares. Bank of America boosted their target price on shares of Tempus AI from $68.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, June 25th. BTIG Research boosted their price objective on shares of Tempus AI from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, August 20th. Morgan Stanley raised their target price on Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 12th. Guggenheim lifted their target price on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, September 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $70.00 price target on shares of Tempus AI in a research report on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tempus AI has an average rating of “Hold” and a consensus target price of $71.83.

Tempus AI Stock Performance

Shares of TEM opened at $87.78 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58. The firm’s fifty day simple moving average is $82.18 and its two-hundred day simple moving average is $66.23. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32. The stock has a market capitalization of $15.25 billion, a P/E ratio of -73.76 and a beta of 4.87.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The company had revenue of $314.64 million for the quarter, compared to the consensus estimate of $296.84 million. During the same period in the previous year, the business earned ($6.86) EPS. The firm’s revenue was up 89.5% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. As a group, analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current year.

Insider Activity

In related news, CEO Eric P. Lefkofsky sold 332,500 shares of the stock in a transaction on Thursday, September 25th. The shares were sold at an average price of $76.56, for a total transaction of $25,456,200.00. Following the transaction, the chief executive officer directly owned 9,141,032 shares of the company’s stock, valued at $699,837,409.92. This represents a 3.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew Polovin sold 5,398 shares of the firm’s stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total transaction of $402,960.70. Following the completion of the sale, the executive vice president owned 132,056 shares of the company’s stock, valued at $9,857,980.40. The trade was a 3.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 933,662 shares of company stock worth $68,070,993. Company insiders own 26.27% of the company’s stock.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.